{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:38:18Z","timestamp":1794577098154,"version":"4.9.1"},"reference-count":134,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073402"],"award-info":[{"award-number":["82073402"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204758"],"award-info":[{"award-number":["82204758"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.isci.2023.107778","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T21:09:27Z","timestamp":1693343367000},"page":"107778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates"],"prefix":"10.1016","volume":"26","author":[{"given":"Zhiwen","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2023.107778_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.isci.2023.107778_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1248\/cpb.c19-00853","article-title":"Antibody-drug conjugate payloads; study of auristatin derivatives","volume":"68","author":"Akaiwa","year":"2020","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.isci.2023.107778_bib3","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/jcm10061332","article-title":"Whole-body pharmacokinetics and physiologically based pharmacokinetic model for monomethyl auristatin E (MMAE)","volume":"10","author":"Chang","year":"2021","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.isci.2023.107778_bib4","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V122.21.848.848","article-title":"A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas","volume":"122","author":"Bartlett","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.isci.2023.107778_bib5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood.V122.21.1809.1809","article-title":"Three-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"122","author":"Pro","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.isci.2023.107778_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-137078","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory diffuse large B-cell lymphoma: updated results of a phase Ib\/II randomized study and preliminary results of a single-arm extension","volume":"136","author":"Sehn","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.isci.2023.107778_bib7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaFDA Approval Summary: Enfortumab Vedotin","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2023.107778_bib8","series-title":"EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la\/mUC)","author":"Petrylak","year":"2019"},{"key":"10.1016\/j.isci.2023.107778_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1\u20132 trial","volume":"20","author":"De Bono","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yrtph.2016.10.012","article-title":"Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic","volume":"82","author":"Stagg","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.isci.2023.107778_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.isci.2023.107778_bib12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2023.107778_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112671","article-title":"Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: an update","volume":"147","author":"Desforges","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.isci.2023.107778_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bcpt.13654","article-title":"Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies","volume":"130","author":"Chua","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.isci.2023.107778_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102831","article-title":"Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings","volume":"145","author":"Ibrahim","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.isci.2023.107778_bib16","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","article-title":"Peripheral neuropathy induced by microtubule-stabilizing agents","volume":"24","author":"Lee","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib120","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107778_bib121","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib122","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.isci.2023.107778_bib123","first-page":"1394","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression. Blood","volume":"125","author":"Jacobsen","year":"2015","journal-title":"The Journal of the American Society of Hematology"},{"key":"10.1016\/j.isci.2023.107778_bib124","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.107778_bib125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.107778_bib126","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107778_bib127","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107778_bib128","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107778_bib129","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2023.107778_bib131","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.isci.2023.107778_bib132","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib133","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-19-2962","article-title":"Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2023.107778_bib134","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib27","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1111\/cas.15443","article-title":"Tisotumab vedotin in Japanese patients with recurrent\/metastatic cervical cancer: Results from the innovaTV 206 study","volume":"113","author":"Yonemori","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.isci.2023.107778_bib17","first-page":"2328","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood","volume":"129","author":"Zinzani","year":"2017","journal-title":"The Journal of the American Society of Hematology"},{"key":"10.1016\/j.isci.2023.107778_bib18","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107778_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107778_bib20","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.isci.2023.107778_bib21","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib22","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107778_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody\u2013drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody\u2013Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial CarcinomaA Phase II Study of RC48-ADC in Advanced Urothelial Carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2023.107778_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review","volume":"8","author":"Kerckhove","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2023.107778_bib30","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.isci.2023.107778_bib31","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4103\/1673-5374.276321","article-title":"Insights into platinum-induced peripheral neuropathy\u2013current perspective","volume":"15","author":"Lazi\u0107","year":"2020","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.isci.2023.107778_bib32","first-page":"S63","article-title":"Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment","volume":"24","author":"Islam","year":"2019","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"key":"10.1016\/j.isci.2023.107778_bib33","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/1545968319860486","article-title":"Neuropathic pain in taxane-induced peripheral neuropathy: evidence for exercise in treatment","volume":"33","author":"Andersen Hammond","year":"2019","journal-title":"Neurorehabilitation Neural Repair"},{"key":"10.1016\/j.isci.2023.107778_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2016.12.007","article-title":"Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect","volume":"103","author":"Kaplan","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.isci.2023.107778_bib35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody\u2013drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.isci.2023.107778_bib36","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrneurol.2014.211","article-title":"Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain","volume":"10","author":"Sisignano","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.isci.2023.107778_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.isci.2023.107778_bib38","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","article-title":"An FDA oncology analysis of antibody-drug conjugates","volume":"71","author":"Saber","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.isci.2023.107778_bib39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.isci.2023.107778_bib40","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug\u2013antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody\u2013maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.isci.2023.107778_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11060-022-04013-8","article-title":"Fc\u03b3 Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates","volume":"158","author":"Aoyama","year":"2022","journal-title":"J.\u00a0Neuro Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2020.101916","article-title":"Axon guidance receptors: Endocytosis, trafficking and downstream signaling from endosomes","volume":"198","author":"Pasterkamp","year":"2021","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.isci.2023.107778_bib43","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody\u2013drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.isci.2023.107778_bib44","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1535-7163.MCT-15-1004","article-title":"Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker DesignMolecular Basis of VC-PABC Linker Instability","volume":"15","author":"Dorywalska","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2023.107778_bib45","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.xphs.2019.01.034","article-title":"A \u201cdual\u201d cell-level systems PK-PD model to characterize the bystander effect of ADC","volume":"108","author":"Singh","year":"2019","journal-title":"J.\u00a0Pharmaceut. Sci."},{"key":"10.1016\/j.isci.2023.107778_bib46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/03602532.2020.1716784","article-title":"Metabolism of bioconjugate therapeutics: Why, when, and how?","volume":"52","author":"Liu","year":"2020","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.isci.2023.107778_bib47","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/bc5005747","article-title":"Effect of attachment site on stability of cleavable antibody drug conjugates","volume":"26","author":"Dorywalska","year":"2015","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.isci.2023.107778_bib48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2017.08.049","article-title":"Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy","volume":"142","author":"Joubert","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.isci.2023.107778_bib49","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1535-7163.MCT-15-1004","article-title":"Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design","volume":"15","author":"Dorywalska","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2023.107778_bib135","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1021\/acs.molpharmaceut.9b00696","article-title":"Optimizing Lysosomal Activation of Antibody\u2013Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers","volume":"16","author":"Salomon","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.isci.2023.107778_bib51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2008.01.008","article-title":"Peripheral nerve damage associated with administration of taxanes in patients with cancer","volume":"66","author":"Argyriou","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.isci.2023.107778_bib52","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMcibr1112481","article-title":"Microtubules, axonal transport, and neuropathy","volume":"365","author":"Holzbaur","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107778_bib53","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41580-022-00491-w","article-title":"Selective motor activation in organelle transport along axons","volume":"23","author":"Cason","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.isci.2023.107778_bib54","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/psp4.12442","article-title":"Time-to-Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine-Citrulline-Monomethylauristatin E Antibody\u2013Drug Conjugates","volume":"8","author":"K\u00e5gedal","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.isci.2023.107778_bib55","first-page":"389","article-title":"Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration","volume":"21","author":"Cavaletti","year":"2000","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.isci.2023.107778_bib56","first-page":"S40","article-title":"Taxane and epothilone-induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24","author":"Tamburin","year":"2019","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"key":"10.1016\/j.isci.2023.107778_bib57","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/978-3-030-73503-6_28","article-title":"Drug-induced peripheral neuropathies","author":"Jain","year":"2021","journal-title":"Drug-induced neurological disorders"},{"key":"10.1016\/j.isci.2023.107778_bib58","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.3390\/ijms20123022","article-title":"The role of endothelial dysfunction in peripheral blood nerve barrier: molecular mechanisms and pathophysiological implications","volume":"20","author":"Maiuolo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2023.107778_bib59","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/0192623319854326","article-title":"Toxic peripheral neuropathies: agents and mechanisms","volume":"48","author":"Valentine","year":"2020","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.isci.2023.107778_bib60","doi-asserted-by":"crossref","DOI":"10.1097\/PR9.0000000000000873","article-title":"Sensory neuron\u2013associated macrophages as novel modulators of neuropathic pain","volume":"6","author":"Silva","year":"2021","journal-title":"Pain Reports"},{"key":"10.1016\/j.isci.2023.107778_bib61","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41467-019-13839-2","article-title":"Dorsal root ganglion macrophages contribute to both the initiation and persistence of neuropathic pain","volume":"11","author":"Yu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2023.107778_bib62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1515\/sjpain-2019-0138","article-title":"Role of the immune system in neuropathic pain","volume":"20","author":"Malcangio","year":"2019","journal-title":"Scand. J. Pain"},{"key":"10.1016\/j.isci.2023.107778_bib63","series-title":"Sigma-1 Receptors Control Neuropathic Pain and Macrophage Infiltration into the Dorsal Root Ganglion after Peripheral Nerve Injury","author":"Bravo Caparr\u00f3s","year":"2020"},{"key":"10.1016\/j.isci.2023.107778_bib64","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/cells12010100","article-title":"Deciphering the Role of Schwann Cells in Inflammatory Peripheral Neuropathies Post Alphavirus Infection","volume":"12","author":"Bedoui","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.isci.2023.107778_bib65","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.tins.2020.07.008","article-title":"How do sensory neurons sense danger signals?","volume":"43","author":"Donnelly","year":"2020","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.isci.2023.107778_bib66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cbin.11914","article-title":"Origin, production and molecular determinants of macrophages for their therapeutic targeting","volume":"47","author":"Chowdhury","year":"2023","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.isci.2023.107778_bib67","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3390\/ijms18112296","article-title":"Pharmacological regulation of neuropathic pain driven by inflammatory macrophages","volume":"18","author":"Kiguchi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2023.107778_bib68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.conb.2019.11.006","article-title":"Regulation of pain by neuro-immune interactions between macrophages and nociceptor sensory neurons","volume":"62","author":"Chen","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.isci.2023.107778_bib69","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fncel.2018.00158","article-title":"Epigenetic modifications associated to neuroinflammation and neuropathic pain after neural trauma","volume":"12","author":"Penas","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.isci.2023.107778_bib70","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s42466-020-00064-2","article-title":"Diagnosis of peripheral neuropathy","volume":"2","author":"Lehmann","year":"2020","journal-title":"Neurol. Res. Pract."},{"key":"10.1016\/j.isci.2023.107778_bib71","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3390\/pharmaceutics13040450","article-title":"Topical treatments and their molecular\/cellular mechanisms in patients with peripheral neuropathic pain\u2014Narrative review","volume":"13","author":"Kocot-K\u0119pska","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.isci.2023.107778_bib72","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3390\/nu12082221","article-title":"B12 as a treatment for peripheral neuropathic pain: a systematic review","volume":"12","author":"Julian","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.isci.2023.107778_bib73","series-title":"The Therapeutic Potential of Antioxidants in Chemotherapy-Induced Peripheral Neuropathy: Evidence from Preclinical and Clinical Studies","first-page":"1","author":"Zhou","year":"2023"},{"key":"10.1016\/j.isci.2023.107778_bib74","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.isci.2023.107778_bib75","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.neurol.2019.11.007","article-title":"Neuropathy of the elderly","volume":"176","author":"Bouche","year":"2020","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.isci.2023.107778_bib76","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0140-6736(05)74815-7","article-title":"Autonomic peripheral neuropathy","volume":"365","author":"Freeman","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.107778_bib77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cai2.8","article-title":"Expert consensus on the clinical application of antibody-drug conjugates in the treatment of malignant tumors (2021 edition)","volume":"1","author":"Center","year":"2022","journal-title":"Cancer Innovation"},{"key":"10.1016\/j.isci.2023.107778_bib78","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.isci.2023.107778_bib79","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","article-title":"Cancer-treatment-induced neurotoxicity\u2014focus on newer treatments","volume":"13","author":"Stone","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib80","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/1078-0432.CCR-11-1425","article-title":"A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies","volume":"18","author":"Fanale","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2023.107778_bib81","first-page":"296","article-title":"Peripheral insensate neuropathy-is height a risk factor?","volume":"7","author":"Kote","year":"2013","journal-title":"J.\u00a0Clin. Diagn. Res."},{"key":"10.1016\/j.isci.2023.107778_bib82","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/psp4.12192","article-title":"Time-to-event analysis of polatuzumab vedotin-induced peripheral neuropathy to assist in the comparison of clinical dosing regimens","volume":"6","author":"Lu","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.isci.2023.107778_bib83","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/01.WNL.0000043691.53710.53","article-title":"Toxic neuropathy in patients with pre-existing neuropathy","volume":"60","author":"Chaudhry","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.isci.2023.107778_bib84","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1212\/01.WNL.0000032505.45389.94","article-title":"Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment","volume":"59","author":"Kalfakis","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.isci.2023.107778_bib85","series-title":"ADCETRIS\u00ae (Brentuximab Vedotin) for Injection, for Intravenous Use","year":"2011"},{"key":"10.1016\/j.isci.2023.107778_bib86","series-title":"POLIVY\u2122 (Polatuzumab Vedotin-Piiq) for Injection, for Intravenous Use","year":"2019"},{"key":"10.1016\/j.isci.2023.107778_bib87","series-title":"PADCEV\u00ae (Enfortumab Vedotin-Ejfv) for Injection, for Intravenous Use","year":"2019"},{"key":"10.1016\/j.isci.2023.107778_bib88","series-title":"TIVDAK TM (Tisotumab Vedotin-Tftv) for Injection, for Intravenous Use","year":"2021"},{"key":"10.1016\/j.isci.2023.107778_bib89","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2023.107778_bib90","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2147\/JPR.S190231","article-title":"Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review","volume":"12","author":"Di Stefano","year":"2019","journal-title":"J.\u00a0Pain Res."},{"key":"10.1016\/j.isci.2023.107778_bib91","doi-asserted-by":"crossref","first-page":"e10263","DOI":"10.1590\/1414-431x202010263","article-title":"Amifostine protects from the peripheral sensory neuropathy induced by oxaliplatin in mice","volume":"53","author":"Pereira","year":"2020","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.isci.2023.107778_bib92","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1089\/acm.2020.0068","article-title":"Efficacy and safety of mecobalamin on peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Sawangjit","year":"2020","journal-title":"J.\u00a0Alternative Compl. Med."},{"key":"10.1016\/j.isci.2023.107778_bib93","first-page":"1","article-title":"Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy","volume":"4","author":"Wright","year":"2010","journal-title":"J.\u00a0Pain Res."},{"key":"10.1016\/j.isci.2023.107778_bib94","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3390\/pharmaceutics14071407","article-title":"Therapeutics for Chemotherapy-Induced Peripheral Neuropathy: Approaches with Natural Compounds from Traditional Eastern Medicine","volume":"14","author":"Chung","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.isci.2023.107778_bib95","series-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update","author":"Loprinzi","year":"2020"},{"key":"10.1016\/j.isci.2023.107778_bib96","doi-asserted-by":"crossref","first-page":"411","DOI":"10.21147\/j.issn.1000-9604.2017.05.05","article-title":"Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy","volume":"29","author":"Wang","year":"2017","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.isci.2023.107778_bib97","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1586\/14737175.2013.814930","article-title":"Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond","volume":"13","author":"Onofrj","year":"2013","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.isci.2023.107778_bib98","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.critrevonc.2015.11.014","article-title":"Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: a systematic review","volume":"98","author":"Brami","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.isci.2023.107778_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105874","article-title":"Acetyl-l-carnitine in chronic pain: A narrative review","volume":"173","author":"Sarzi-Puttini","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.isci.2023.107778_bib100","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.2012.44.8738","article-title":"Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy","volume":"31","author":"Hershman","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib101","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jnci\/djx259","article-title":"Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715)","volume":"110","author":"Hershman","year":"2018","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.isci.2023.107778_bib102","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000502979","article-title":"Use of amifostine for cytoprotection during radiation therapy: a review","volume":"98","author":"King","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.isci.2023.107778_bib103","first-page":"S26","article-title":"Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24","author":"Staff","year":"2019","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"key":"10.1016\/j.isci.2023.107778_bib104","first-page":"571","article-title":"The randomized controlled trial of amifostine in improving neurotoxicity induced by oxaliplatin on gastroenteric tumor patient","volume":"12","author":"Wang","year":"2014","journal-title":"Oncology Progress"},{"key":"10.1016\/j.isci.2023.107778_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135484","article-title":"Analysis of the effect of probucol-mecobalamin tablets combination on oxidative stress in patients with diabetic peripheral neuropathy","volume":"741","author":"Peng","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.isci.2023.107778_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112717","article-title":"Progress in the treatment of diabetic peripheral neuropathy","volume":"148","author":"Yang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.isci.2023.107778_bib107","doi-asserted-by":"crossref","first-page":"e200681","DOI":"10.1001\/jamanetworkopen.2020.0681","article-title":"Effect of acupuncture vs sham procedure on chemotherapy-induced peripheral neuropathy symptoms: a randomized clinical trial","volume":"3","author":"Bao","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.isci.2023.107778_bib108","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.breast.2019.12.011","article-title":"Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial","volume":"49","author":"Kanbayashi","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.isci.2023.107778_bib109","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/cancers13040766","article-title":"Emerging pharmacological and non-pharmacological therapeutics for prevention and treatment of chemotherapy-induced peripheral neuropathy","volume":"13","author":"Li","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2023.107778_bib110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1213\/ANE.0000000000001581","article-title":"Continuous peripheral nerve blocks: an update of the published evidence and comparison with novel, alternative analgesic modalities","volume":"124","author":"Ilfeld","year":"2017","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.isci.2023.107778_bib111","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1002\/cbic.201900178","article-title":"Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody\u2013Drug Conjugates","volume":"20","author":"Yamada","year":"2019","journal-title":"Chembiochem"},{"key":"10.1016\/j.isci.2023.107778_bib112","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1021\/acs.molpharmaceut.1c00473","article-title":"Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody\u2013Drug Conjugates","volume":"18","author":"Matsuda","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.isci.2023.107778_bib113","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nbt.3274","article-title":"Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading","volume":"33","author":"Strop","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2023.107778_bib114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody\u2013drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.isci.2023.107778_bib115","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/biomedicines9080872","article-title":"Advances and limitations of antibody drug conjugates for cancer","volume":"9","author":"Mckertish","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2023.107778_bib116","doi-asserted-by":"crossref","first-page":"17133","DOI":"10.1021\/jacs.9b05833","article-title":"Copper-triggered bioorthogonal cleavage reactions for reversible protein and cell surface modifications","volume":"141","author":"Wang","year":"2019","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.isci.2023.107778_bib117","first-page":"14740","article-title":"Innovative linker strategies for tumor-targeted drug conjugates","volume":"25","author":"Dal Corso","year":"2019","journal-title":"Chemistry (Basel)."},{"key":"10.1016\/j.isci.2023.107778_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101223","article-title":"Nanotechnology for pain management: Current and future therapeutic interventions","volume":"39","author":"Bhansali","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.isci.2023.107778_bib119","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2174\/1389201024666230123150856","article-title":"Cancer-induced Pain Management by Nanotechnology-based Approach","volume":"24","author":"Dash","year":"2023","journal-title":"Curr. Pharmaceut. Biotechnol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223018552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223018552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T14:56:46Z","timestamp":1754405806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004223018552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":134,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2589004223018552"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2023.107778","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2023.107778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"107778"}}